Structure Therapeutics is trading 4.9% higher at $54.14 in pre-market action, staging a partial recovery after two consecutive sessions of profit taking.
- The stock's recent rally was driven by positive Phase 2 data for its oral GLP-1 obesity treatment and successful financing news.
- With no fresh company-specific catalysts this morning, the move suggests a technical rebound as investors reassess recent weakness amid mixed broader market futures.